ALKERMES | ALKS - 净收入

金融业

USD

USD 4.39B

现金及等价物

USD 511.53M

USD 120.7M

USD 1.52B

USD 662.09M

USD 1.58B

股息收益率

0

USD -65.93M

USD 139.22M

1.8K

EPS每股收益

USD 0

股本和储备

USD 1.81B

USD 375.31M

债务利息支出

USD 25.93M

USD 8.54M

USD 1.48B

USD 7.56B

USD 501K

USD 1.81B

USD -65.93M

普通股股本

USD 167.54M

135.81

USD -61.93M

USD 496.01M

销售和管理费用

USD 196.64M

USD 298.96M

贸易债权人

USD 142.86M

应收帐款人

USD 456.48M

	净收入	更改		日
AbbVie	USD 3.61B		2.92B	2026-06
Acadia Pharmaceuticals	USD 31.5M		27.86M	2026-06
ALKERMES	USD 501K		66.98M	2026-06
Amgen	USD 2.38B		556M	2026-06
Biogen	USD 97.5M		222M	2026-06
BioMarin Pharmaceutical	USD 44.76M		60.76M	2026-06
Bristol-Myers Squibb	USD 3.32B		640M	2026-06
Coherus Biosciences	USD -37.64M		2.11M	2025-12
Eli Lilly	USD 7.1B		301M	2026-06
Gilead Sciences	USD -10.5B		12.52B	2026-06
Heron Therapeutics	USD -2.95M		14.54M	2025-12
Ionis Pharmaceuticals	USD -114.65M		21.65M	2026-06
J&J	USD 5.53B		299M	2026-06
Malin Corporation	EUR -1.1M		2.2M	2023-12
Merck	USD -1.34B		2.9B	2026-06
Minerva Neurosciences	USD 1.44M		21.07M	2024-12
Nektar Therapeutics	USD -44.9M		8.82M	2026-03
Neurocrine Biosciences	USD 144.4M		53.5M	2026-06
Otsuka Holdings	JPY 117.26B		18.92B	2026-06
Ovoca Bio	EUR 4.42M		5.19M	2025-12
Pfizer	USD -248M		2.94B	2026-06
Regeneron Pharmaceuticals	USD 1.3B		569.7M	2026-06
Vertex Pharmaceuticals	USD 1.1B		68.4M	2026-06